THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [8.9] ID: TIP-MED-000137

Levofloxacin Hemihydrate

Active Ingredient / Scientific Identity: Levofloxacin Hemihydrate • Class: Third-Generation ('Respiratory') Fluoroquinolone Antibiotic (L-Isomer of Ofloxacin; Bactericidal; WHO 'Watch' Group)

⚖️ Compare Profile
Generic / Entity NameLevofloxacin Hemihydrate ([8.9])
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassThird-Generation ('Respiratory') Fluoroquinolone Antibiotic (L-Isomer of Ofloxacin; Bacter
Available Dosage FormsOral Film-Coated Tablets: 250 mg, 500 mg, 750 mg; IV Infusion: 500 mg/100 mL
Regulatory ClassificationSchedule H1 Prescription Drug (Mandatory Red-Bordered Rx Warning & 3-Year Register un
Key Warning & Review DateRenal: STRICTLY RENAL-FUNCTION DEPENDENT (Excreted >85% unchanged in urine—even more renally dependent than ciprofloxacin)! •
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Schedule H1 Prescription Drug (Mandatory Red-Bordere✔️ Standard Clinical Dispensing Precautions

1. Clinical & Scientific Overview

Levofloxacin Hemihydrate (TIP-MED-000137, Reference Code [8.9]) is classified under Antimicrobials — Antibacterial & Antibiotic Agents (Ch 08) as a Third-Generation ('Respiratory') Fluoroquinolone Antibiotic (L-Isomer of Ofloxacin; Bactericidal; WHO 'Watch' Group). Within the Indian regulatory and compendial framework, it is governed under Schedule H1 Prescription Drug (Mandatory Red-Bordered Rx Warning & 3-Year Register under Rule 65 of Drugs Rules 1945).

Verified Indian Market Examples / Compendial Status:
Representative Indian Market Examples (Edition 2.7 Ch 08 [8.9], p. 97): Levoflox (Cipla), Glevo (Glenmark), Levomac (Macleods), Tavanic (Sanofi), L-Cin (Lupin), Fynal — Strengths & Dosage Forms: Oral Film-Coated Tablets: 250 mg, 500 mg, 750 mg; IV Infusion: 500 mg/100 mL
Representative Indian Market Examples (Edition 2.7 Ch 08 [8.9], p. 97): Levoflox (Cipla), Glevo (Glenmark), Levomac (Macleods), Tavanic (Sanofi), L-Cin (Lupin), Fynal — Strengths & Dosage Forms: Oral Film-Coated Tablets: 250 mg, 500 mg, 750 mg; IV Infusion: 500 mg/100 mL
Dosage Forms & Available Strengths:
Oral Film-Coated Tablets: 250 mg, 500 mg, 750 mg; IV Infusion: 500 mg/100 mL
Routes: Oral / Parenteral / Topical as specified by formulation

3. Mechanism of Action & Pharmacodynamics

Third-Generation ('Respiratory') Fluoroquinolone Antibiotic (L-Isomer of Ofloxacin; Bactericidal; WHO 'Watch' Group) acting on target receptor/enzyme pathways in Antimicrobials — Antibacterial & Antibiotic Agents (Ch 08): clinical efficacy is mediated via Third-Generation ('Respiratory') Fluoroquinolone Antibiotic (L-Isomer of Ofloxacin; Bactericidal; WHO 'Watch' Group) for Community-acquired pneumonia (with enhanced Streptococcus pneumoniae and atypical pathogen coverage compared to ciprofloxacin), complicated urinary tract infections and acute pyelonephritis, chronic bacterial prostatitis, complicated skin/soft-tissue infections, and second-line multidrug-resistant tuberculosis (MDR-TB) regimens. (Never use empirically in patients with cough >2 weeks before ruling out Pulmonary TB!)..

4. Therapeutic Indications & Evidence-Supported Uses

  • Community-acquired pneumonia (with enhanced Streptococcus pneumoniae and atypical pathogen coverage compared to ciprofloxacin), complicated urinary tract infections and acute pyelonephritis, chronic bacterial prostatitis, complicated skin/soft-tissue infections, and second-line multidrug-resistant tuberculosis (MDR-TB) regimens
  • (Never use empirically in patients with cough >2 weeks before ruling out Pulmonary TB!)

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: General Adult Reference: 500 mg once daily for 7–14 days (or 750 mg once daily for 5 days in CAP/acute pyelonephritis/sinusitis; 250 mg once daily for 3 days in uncomplicated UTI). Dosing strictly depends on renal CrCl! Follow physician prescription.

Administration & Meal Timing: With or without food (unlike ciprofloxacin, ordinary milk/meals do not substantially impair levofloxacin absorption, HOWEVER polyvalent metal cations [Calcium, Iron, Zinc, Magnesium/Aluminium Antacids, Sucralfate] STILL chelate and block levofloxacin absorption!). | Once daily in the morning (morning dosing reduces fluoroquinolone-induced nocturnal insomnia and vivid dreams).

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Metabolism & Biotransformation:
Renal: STRICTLY RENAL-FUNCTION DEPENDENT (Excreted >85% unchanged in urine—even more renally dependent than ciprofloxacin)! • CrCl ≥50 mL/min: Standard dose (500 mg or 750 mg every 24 h). • CrCl 20–49 mL/min: For 500 mg regimen -> 500 mg initial dose on Day 1, then 250 mg once every 24 hours (For 750 mg regimen -> 750 mg once every 48 hours). • CrCl 10–19 mL/min or Dialysis: For 500 mg regimen -> 500 mg initial dose on Day 1, then 125 mg–250 mg once every 48 hours! Hepatic: No hepatic metabolism; no adjustment required.
Elimination & Renal Adjustment:
Renal: STRICTLY RENAL-FUNCTION DEPENDENT (Excreted >85% unchanged in urine—even more renally dependent than ciprofloxacin)! • CrCl ≥50 mL/min: Standard dose (500 mg or 750 mg every 24 h). • CrCl 20–49 mL/min: For 500 mg regimen -> 500 mg initial dose on Day 1, then 250 mg once every 24 hours (For 750 mg regimen -> 750 mg once every 48 hours). • CrCl 10–19 mL/min or Dialysis: For 500 mg regimen -> 500 mg initial dose on Day 1, then 125 mg–250 mg once every 48 hours! Hepatic: No hepatic metabolism; no adjustment required.
Hepatic Impairment Considerations:
Renal: STRICTLY RENAL-FUNCTION DEPENDENT (Excreted >85% unchanged in urine—even more renally dependent than ciprofloxacin)! • CrCl ≥50 mL/min: Standard dose (500 mg or 750 mg every 24 h). • CrCl 20–49 mL/min: For 500 mg regimen -> 500 mg initial dose on Day 1, then 250 mg once every 24 hours (For 750 mg regimen -> 750 mg once every 48 hours). • CrCl 10–19 mL/min or Dialysis: For 500 mg regimen -> 500 mg initial dose on Day 1, then 125 mg–250 mg once every 48 hours! Hepatic: No hepatic metabolism; no adjustment required.

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • Same Class Boxed Warnings as Ciprofloxacin: Achilles tendinitis and tendon rupture (especially >60 years or with corticosteroids), peripheral neuropathy, CNS toxicity (delirium, hallucinations, seizures), aortic aneurysm/dissection, myasthenia gravis exacerbation, QTc prolongation, and severe dysglycaemia.

Key Clinical Precautions: Renal: STRICTLY RENAL-FUNCTION DEPENDENT (Excreted >85% unchanged in urine—even more renally dependent than ciprofloxacin)! • CrCl ≥50 mL/min: Standard dose (500 mg or 750 mg every 24 h). • CrCl 20–49 mL/min: For 500 mg regimen -> 500 mg initial dose on Day 1, then 250 mg once every 24 hours (For 750 mg regimen -> 750 mg once every 48 hours). • CrCl 10–19 mL/min or Dialysis: For 500 mg regimen -> 500 mg initial dose on Day 1, then 125 mg–250 mg once every 48 hours! Hepatic: No hepatic metabolism; no adjustment required.

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Nausea, diarrhoea, headache, insomnia, dizziness, photosensitivity.
  • Tendon rupture, severe hypoglycaemia (and hyperglycaemic coma) in elderly diabetics, QTc interval prolongation / torsades de pointes, acute delirium/psychosis in the elderly, C. difficile colitis, hepatotoxicity.
Serious / Dose-Limiting Adverse Effects:
  • Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

  • Chelation Blockade: Separate from Calcium, Iron, Zinc, Multivitamins, Antacids, and Sucralfate by at least 2 hours before or 2–4 hours after! (Note: Unlike ciprofloxacin, levofloxacin does NOT inhibit CYP1A2, so it does not interact with theophylline, tizanidine, or caffeine!)
  • However, it has strong additive QTc prolongation with Amiodarone, Sotalol, Domperidone, Ondansetron, Azithromycin, and Escitalopram; potentiates Warfarin INR; causes severe hypoglycaemia with Sulfonylureas and Insulin; and increases seizure risk with NSAIDs

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.

Pharmacist Patient Counselling Points:

  • Patient Counselling Checklist: Take once daily in the morning, spaced at least 2 hours away from any Calcium, Iron, Zinc, or Antacid medicine. Stop immediately and inform the doctor if heel/calf tendon pain, numbness/tingling in hands/feet, confusion, or low blood sugar sweats occur. Protect skin from harsh sunlight.
  • Meal & Clock Timing Instruction: With or without food (unlike ciprofloxacin, ordinary milk/meals do not substantially impair levofloxacin absorption, HOWEVER polyvalent metal cations [Calcium, Iron, Zinc, Magnesium/Aluminium Antacids, Sucralfate] STILL chelate and block levofloxacin absorption!). (Once daily in the morning (morning dosing reduces fluoroquinolone-induced nocturnal insomnia and vivid dreams).)
  • Missed Dose Protocol: Take as soon as remembered on the same day (spaced 2 hours from calcium/iron); never double.
  • Geriatric Dispensing Pearl: Because >85% of levofloxacin is cleared unchanged by the kidneys, giving standard 500 mg or 750 mg daily to an 80-year-old CGHS patient with CrCl 25–40 mL/min causes rapid CNS accumulation (presenting as acute agitation, visual hallucinations, or seizures), Achilles tendon rupture (especially if co-prescribed Prednisolone for COPD!), and severe hypoglycaemia.

Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Oral Film-Coated Tablets: 250 mg, 500 mg, 750 mg; IV Infusion: 500 mg/100 mL

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 08 [8.9] (p. 97)

Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.